| Code | Description | Claims | Beneficiaries | Total Paid |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,327 |
2,583 |
$1.35M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
5,001 |
4,219 |
$825K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
3,667 |
2,583 |
$790K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,693 |
4,942 |
$535K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,698 |
1,726 |
$531K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
2,804 |
2,468 |
$527K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,213 |
1,579 |
$495K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,474 |
5,300 |
$487K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,681 |
1,213 |
$476K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,068 |
3,834 |
$277K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
5,544 |
4,355 |
$276K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
993 |
846 |
$189K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,365 |
2,055 |
$144K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
7,398 |
3,121 |
$142K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,695 |
1,476 |
$135K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,653 |
2,380 |
$96K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
3,451 |
3,004 |
$86K |
| 80053 |
Comprehensive metabolic panel |
10,230 |
8,441 |
$74K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
930 |
822 |
$73K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
14,382 |
11,432 |
$73K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,555 |
4,164 |
$61K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
2,315 |
980 |
$60K |
| 71046 |
Radiologic examination, chest; 2 views |
2,207 |
1,566 |
$60K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
183 |
128 |
$59K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
5,974 |
4,931 |
$47K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
201 |
124 |
$45K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
935 |
868 |
$44K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,585 |
1,469 |
$42K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
119 |
103 |
$41K |
| 73630 |
|
997 |
680 |
$39K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
179 |
129 |
$35K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
594 |
511 |
$35K |
| 36000 |
|
492 |
433 |
$33K |
| 80061 |
Lipid panel |
2,127 |
1,990 |
$31K |
| 71045 |
Radiologic examination, chest; single view |
5,957 |
3,735 |
$30K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
2,088 |
889 |
$29K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
846 |
762 |
$28K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
855 |
770 |
$28K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
13 |
12 |
$26K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,776 |
2,570 |
$25K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,348 |
1,158 |
$25K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,849 |
3,098 |
$25K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,660 |
3,015 |
$24K |
| 84484 |
|
5,769 |
3,160 |
$23K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
1,617 |
778 |
$22K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
606 |
541 |
$22K |
| 97162 |
|
485 |
458 |
$19K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
426 |
304 |
$18K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
1,128 |
966 |
$16K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,016 |
2,600 |
$16K |
| 81025 |
|
1,863 |
1,678 |
$15K |
| 73562 |
|
404 |
269 |
$14K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
95 |
75 |
$14K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
271 |
176 |
$13K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
331 |
279 |
$13K |
| 83690 |
|
3,160 |
2,620 |
$12K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,972 |
1,388 |
$12K |
| 81001 |
|
5,511 |
4,618 |
$12K |
| 83735 |
|
3,812 |
3,139 |
$12K |
| G0378 |
Hospital observation service, per hour |
694 |
400 |
$11K |
| 82805 |
|
886 |
668 |
$11K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
166 |
151 |
$10K |
| 87077 |
|
1,828 |
1,391 |
$10K |
| 87040 |
|
3,056 |
1,409 |
$10K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,451 |
2,703 |
$9K |
| 85379 |
|
1,980 |
1,740 |
$9K |
| 73502 |
|
306 |
197 |
$9K |
| 83880 |
|
934 |
772 |
$9K |
| 83605 |
|
2,358 |
1,781 |
$9K |
| 73610 |
|
292 |
208 |
$8K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
327 |
79 |
$8K |
| 36415 |
Collection of venous blood by venipuncture |
11,463 |
8,812 |
$8K |
| 85610 |
|
2,431 |
1,604 |
$8K |
| 84145 |
|
1,045 |
889 |
$8K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
111 |
99 |
$8K |
| 84439 |
|
951 |
861 |
$8K |
| 87186 |
|
1,708 |
1,326 |
$8K |
| 86618 |
|
558 |
513 |
$7K |
| 81003 |
|
3,465 |
3,032 |
$7K |
| 82565 |
|
1,718 |
1,461 |
$7K |
| 86140 |
|
1,983 |
1,731 |
$6K |
| 84460 |
|
1,874 |
1,627 |
$6K |
| 82728 |
|
537 |
473 |
$6K |
| 80047 |
|
473 |
419 |
$5K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
304 |
211 |
$5K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
188 |
158 |
$4K |
| 73030 |
|
185 |
122 |
$4K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
18 |
14 |
$4K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
2,304 |
1,983 |
$4K |
| 96367 |
|
34 |
28 |
$4K |
| 84450 |
|
1,304 |
1,144 |
$4K |
| 85027 |
|
1,041 |
903 |
$4K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
7,320 |
5,584 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
231 |
137 |
$3K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,835 |
1,322 |
$3K |
| 82962 |
|
1,983 |
1,025 |
$3K |
| 82947 |
|
717 |
634 |
$3K |
| 82247 |
|
1,213 |
1,051 |
$3K |
| 82040 |
|
968 |
857 |
$3K |
| 97113 |
|
77 |
25 |
$3K |
| 84075 |
|
1,079 |
951 |
$2K |
| 80050 |
General health panel |
167 |
140 |
$2K |
| 84703 |
|
329 |
280 |
$2K |
| 82077 |
|
229 |
171 |
$2K |
| 73130 |
|
54 |
38 |
$2K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
68 |
52 |
$2K |
| 73110 |
|
45 |
27 |
$2K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
13 |
13 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,957 |
1,467 |
$2K |
| 82248 |
|
840 |
747 |
$2K |
| 82803 |
|
182 |
158 |
$2K |
| 80306 |
|
114 |
94 |
$1K |
| 85652 |
|
681 |
602 |
$1K |
| 96376 |
|
552 |
398 |
$1K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
115 |
94 |
$1K |
| 74018 |
|
56 |
39 |
$1K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
23 |
21 |
$1K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
28 |
12 |
$958.20 |
| 82607 |
|
69 |
64 |
$908.75 |
| 97161 |
|
14 |
14 |
$751.92 |
| 99201 |
|
15 |
14 |
$698.84 |
| 85018 |
|
376 |
308 |
$696.19 |
| 83550 |
|
126 |
109 |
$686.28 |
| 86580 |
|
34 |
31 |
$657.94 |
| 87210 |
|
104 |
91 |
$568.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
34 |
26 |
$536.80 |
| 83540 |
|
126 |
109 |
$508.44 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
586 |
355 |
$486.65 |
| 73560 |
|
21 |
12 |
$454.69 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
3,686 |
2,647 |
$343.07 |
| J7050 |
Infusion, normal saline solution, 250 cc |
3,851 |
2,184 |
$334.33 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
939 |
753 |
$258.22 |
| 77073 |
|
15 |
12 |
$250.56 |
| 97163 |
|
28 |
26 |
$243.33 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
788 |
535 |
$222.69 |
| 83655 |
|
14 |
12 |
$175.14 |
| 86703 |
|
12 |
12 |
$170.04 |
| 86850 |
|
56 |
50 |
$166.61 |
| 86900 |
|
48 |
41 |
$162.34 |
| 80051 |
|
40 |
38 |
$150.01 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,235 |
1,088 |
$134.10 |
| J2704 |
Injection, propofol, 10 mg |
686 |
363 |
$104.06 |
| 82043 |
|
15 |
13 |
$91.70 |
| 86901 |
|
49 |
41 |
$77.25 |
| 94761 |
|
479 |
371 |
$41.86 |
| 85730 |
|
20 |
14 |
$37.26 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,505 |
1,906 |
$17.36 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
67 |
56 |
$3.55 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
30 |
26 |
$2.05 |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
34 |
29 |
$1.96 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
32 |
26 |
$1.36 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
229 |
171 |
$0.59 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
165 |
150 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
69 |
49 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
33 |
24 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
80 |
76 |
$0.00 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
18 |
15 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
65 |
55 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
12 |
12 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
15 |
12 |
$0.00 |
| J3535 |
Drug administered through a metered dose inhaler |
21 |
13 |
$0.00 |